Status: current, Not sufficiently defined by necessary conditions definition status. Date: 30-Sep 2021. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4636049012 | Teneligliptin hydrobromide (substance) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 4636050012 | Teneligliptin hydrobromide | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Teneligliptin hydrobromide | Is a | Substance with enzyme inhibitor mechanism of action | false | Inferred relationship | Existential restriction modifier | ||
| Teneligliptin hydrobromide | Is a | Substance with dipeptidyl peptidase IV inhibitor mechanism of action | true | Inferred relationship | Existential restriction modifier | ||
| Teneligliptin hydrobromide | Is a | Carboxylic acid and/or carboxylic acid derivative | true | Inferred relationship | Existential restriction modifier | ||
| Teneligliptin hydrobromide | Has disposition | Dipeptidyl peptidase IV inhibitor | true | Inferred relationship | Existential restriction modifier | ||
| Teneligliptin hydrobromide | Is modification of | Teneligliptin | true | Inferred relationship | Existential restriction modifier | ||
| Teneligliptin hydrobromide | Is a | Drug or medicament | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Product containing precisely teneligliptin (as teneligliptin hydrobromide) 20 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | True | Teneligliptin hydrobromide | Inferred relationship | Existential restriction modifier | 1 |
This concept is not in any reference sets
FHIR